Novartis Buying Regulus In Up To $1.7B Kidney Drug Deal
Novartis AG said Wednesday it has agreed to acquire Latham & Watkins LLP-advised Regulus Therapeutics Inc. for up to $1.7 billion in a deal that strengthens the Swiss pharmaceutical giant's kidney...To view the full article, register now.
Already a subscriber? Click here to view full article